Belmont Dialysis Center is a medicare approved dialysis facility center in Belmont, North Carolina and it has 18 dialysis stations. It is located in Gaston county at 5010 Medical Care Court, Belmont, NC, 28012. You can reach out to the office of Belmont Dialysis Center at (704) 827-2931. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Belmont Dialysis Center has the following ownership type - Profit. It was first certified by medicare in March, 2007. The medicare id for this facility is 342652 and it accepts patients under medicare ESRD program.
| Name | Belmont Dialysis Center |
|---|---|
| Location | 5010 Medical Care Court, Belmont, North Carolina |
| No. of Dialysis Stations | 18 |
| Medicare ID | 342652 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 5010 Medical Care Court, Belmont, North Carolina, 28012 | |
| (704) 827-2931 | |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
| NPI Number | 1992886006 |
| Organization Name | Fresenius Medical Care Belmont |
| Doing Business As | Bio-medical Applications Of North Carolina, Inc. |
| Address | 5010 Medical Care Court Belmont, North Carolina, 28012 |
| Phone Number | (704) 827-2931 |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 68% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 12% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 20% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 66% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 16% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 18% | 14% |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 61% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 23% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 16% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 59% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 32% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 12% |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 78% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 22% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 72% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 18% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 12% |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 34 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 21 |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 64 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 628 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Belmont Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 72 |
| Hypercalcemia patient months | 700 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 76 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 29 |
| Patients with Serumphosphor greater than 7 mg/dL | 15 |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 69 |
| Patient months included in arterial venous fistula and catheter summaries | 487 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 72 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 10 |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 72 |
| Hospitalization Rate in facility | 154.9 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 285.4 |
| Hospitalization Rate: Lower Confidence Limit | 86.9 |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Belmont Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 32.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 44.4 |
| Readmission Rate: Lower Confidence Limit | 21.5 |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Belmont Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.03 (As Expected) |
| SIR: Upper Confidence Limit | 2.49 |
| SIR: Lower Confidence Limit | .33 |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Belmont Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 52 |
| Transfusion Rate in facility | 22.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 95.3 |
| Transfusion Rate: Lower Confidence Limit | 6.4 |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Belmont Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 303 |
| Mortality Rate in facility | 16.6 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 22.9 |
| Mortality Rate: Lower Confidence Limit | 11.7 |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago
Belmont Dialysis Center Location: 5010 Medical Care Court, Belmont, North Carolina, 28012 Phone: (704) 827-2931 |
News Archive
The discovery of a 10-year-old's body at an ancient Roman site in Italy suggests measures were taken to prevent the child, possibly infected with malaria, from rising from the dead and spreading disease to the living.
New findings from a long-term study of men with early-stage, initially untreated prostate cancer suggests that the risk of progression to more aggressive and lethal disease increases significantly in the long-term, according to a study published in the June 9 issue of The Journal of the American Medical Association (JAMA).
Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.
Phagelux, Inc., a leading anti-bacterial company developing phage-based solutions, is pleased to announce the acquisition of several biodegradable polymer delivery systems from Iveria Technologies, Inc., a U.S.-based development company specializing in such technologies.
Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.
› Verified 2 days ago